Sanofi: progress in an antibody with Innate

(CercleFinance.com) - Innate Pharma announces that Sanofi has decided to advance IPH6101/SAR443579, an antibody using Innate's proprietary multi-specific antibody format, to regulatory preclinical studies for the study of an investigational new drug.


This decision has triggered a 7 million euro milestone payment to Innate by Sanofi, which will be responsible for the development, manufacturing and marketing of IPH6101/SAR443579 under their collaboration and licensing agreement.


Copyright (c) 2021 CercleFinance.com. All rights reserved.